Biotek-snakken — Maj 2023
-
UPDATE: FDA needs more time for Sarepta's DMD gene therapy—spurring a deja vu of Exondys 51
(May 24, 2023 08:39am)
"The FDA needs a wee bit more time to consider the approval of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD), however, the agency has indicated an accelerated approval is likely in a restricted age group."
-
RBC Capital Markets har sat et nyt Sarepta Therapeutics kursmål på USD 218 med anbefalingen Outperform ... RBC ser en smule negativt på meldingen fra FDA men anbefaler dog at købe på et tilbagefald.
https://pbs.twimg.com/media/FxA6F9NWIAI6SCZ?format=png&name=900x900
-
BIOTEC: Euforien i 2020 ga kunstig høy verdsettelse, men nå har verdier for 24,2 milliarder kroner forduftet blant biotek-aksjene på Oslo Børs de seneste to årene. – Hele bioteknologisektoren globalt har fått seg en smell. Det er syklisk, og jeg har etter 23 år i bransjen vært med på noen opp- og nedturer, sier Jónas Einarsson i Radforsk. (Fa+)
-
Bioporto vil rejse tocifret millionbeløb via salg af nye aktier til 1 kr. per styk
https://www.proinvestor.com/investornyt/993487/bioporto-vil-rejse-tocifret-millionbelob-via-salg-af-nye-aktier-til-1-kr-per-styk -
Bioportos emissioner minder om en kvindes cyklus. Emissioner og menstruationer falder med stor regelsmæssighed
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind